GlassScriptPhysician profile
Vijayakumar Paramasivam
NPI 1417180878
$4,748.72
in general payments reported to CMS, 2019-2025
22 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $23.97 · 2023: $734 · 2024: $2,693 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955 · Travel and Lodging: $1,481 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.98 |
| Travel and Lodging | $1,481.01 |
| Education | $143.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,036.58 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $522.74 | 2022-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $483.44 | 2021-2025 | Ultomiris, Soliris |
| Travere Therapeutics, INC. | $338.46 | 2023-2025 | |
| Medtronic, INC. | $253.88 | 2024 | Ellipsys Vascular Access System |
| Otsuka America Pharmaceutical, INC. | $205.82 | 2022-2025 | Jynarque |
| Amgen INC. | $179.99 | 2023-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $106.81 | 2024-2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $90.55 | 2023-2024 | Givlaari, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.71 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $69.22 | 2023-2025 | Benlysta |
| Novo Nordisk INC | $68.32 | 2024-2025 | Ozempic |
| Akebia Therapeutics INC | $50.20 | 2024-2025 | Vafseo, Auryxia |
| Daiichi Sankyo INC. | $43.91 | 2023 | Injectafer |
| Aurinia Pharma U.S., INC. | $43.00 | 2023-2025 | Lupkynis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $38.11 | 2023 | Rayaldee |
| Vifor Pharma, INC. | $35.27 | 2023 | Korsuva, Veltassa |
| Apellis Pharmaceuticals, INC. | $23.10 | 2025 | Empaveli |
| One Lambda, INC. | $20.25 | 2024 | |
| Lilly USA, LLC | $19.71 | 2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $19.50 | 2023 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijayakumar Paramasivam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.